VRCA
Verrica Pharmaceuticals Inc.Company with tickers: VRCA
CIK
1660334
CUSIP
92511W207
Shares Outstanding
17,178,786
13F Activity (30d)
39 filings
36 filers
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | $3,439,000 | USD | 2025-03-31 | 10-Q | 2026-05-12 |
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $11,569,000 | USD | 2025-03-31 | 10-Q | 2026-05-12 |
| Research & Development | $2,284,000 | USD | 2025-03-31 | 10-Q | 2026-05-12 |
| Operating Income | $-9,715,000 | USD | 2026-03-31 | 10-Q | 2026-05-12 |
| Net Income | $-9,742,000 | USD | 2025-03-31 | 10-Q | 2026-05-12 |
| EPS (Basic) | $-1.03 | USD/shares | 2025-03-31 | 10-Q | 2026-05-12 |
| EPS (Diluted) | $-1.03 | USD/shares | 2025-03-31 | 10-Q | 2026-05-12 |